There are 702 resources available
185P - The combined role of patients (pts) gender and disease etiology on unresectable HCC (uHCC) first-line (1L) treatment outcome
Presenter: Silvia Cesario
Session: Poster Display session
186P - Patients’ characteristics, outcomes, and costs of liver transplantation in patients with hepatocellular carcinoma in Germany
Presenter: Simone Schrodi
Session: Poster Display session
187P - Use of systemic therapy in patients with intermediate stage hepatocellular carcinoma (HCC): A global needs assessment study of oncologists
Presenter: James White
Session: Poster Display session
188P - Early mortality in atezolizumab/bevacizumab for unresectable hepatocellular carcinoma: European, real-world study
Presenter: Najib Ben Khaled
Session: Poster Display session
189P - The synergic effect of metformin and atezolizumab/bevacizumab in diabetic HCC patients: A retrospective study from ARTE multicentric Italian dataset
Presenter: Andrea Dalbeni
Session: Poster Display session
190P - The role of liver biopsy for unsettled HCC diagnosis: A single-center experience
Presenter: Khaled Abouelkhair
Session: Poster Display session
191P - Evaluating sorafenib as second-line treatment for advanced hepatocellular carcinoma: SORA-2, an European retrospective multicenter study
Presenter: Christian Möhring
Session: Poster Display session
192P - Prevalence of metabolic syndrome among patients with hepatocellular carcinoma of different etiologies: A retrospective study
Presenter: DaLong Yang
Session: Poster Display session
193P - The association between FGF19 expression and clinical outcomes in unresectable hepatocellular carcinoma (uHCC) patients (pts) receiving immune checkpoint inhibitor (ICI)-based therapies
Presenter: Qi Cheng
Session: Poster Display session
195P - Risk factors in patients with hepatocellular carcinoma: A German claims data analysis
Presenter: Selina Becht
Session: Poster Display session